The estimated Net Worth of Karen J May is at least $409 Tausend dollars as of 5 February 2019. Karen May owns over 3,287 units of Baxter International stock worth over $409,390 and over the last 21 years Karen sold BAX stock worth over $0.
Karen has made over 10 trades of the Baxter International stock since 2005, according to the Form 4 filled with the SEC. Most recently Karen exercised 3,287 units of BAX stock worth $93,811 on 5 February 2019.
The largest trade Karen's ever made was exercising 66,160 units of Baxter International stock on 1 November 2017 worth over $1,276,888. On average, Karen trades about 2,377 units every 110 days since 2003. As of 5 February 2019 Karen still owns at least 10,425 units of Baxter International stock.
You can see the complete history of Karen May stock trades at the bottom of the page.
Karen's mailing address filed with the SEC is MONDELEZ INTERNATIONAL, INC., THREE PARKWAY NORTH, DEERFIELD, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney und Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: